SCHEMBL722862

SCHEMBL722862

Fc1cc(F)cc(-c2cc3nccc(Cl)c3o2)c1

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.36
SIRT1 Q96EB6 1/20 0.33
GRM5 P41594 3/20 0.32
MAPK14 Q16539 1/20 0.31
NOTUM Q6P988 1/20 0.31
CYP1A1 P04798 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP1B1 Q16678 1/20 0.31
NISCH Q9Y2I1 1/20 0.30
SLC9A1 P19634 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724007 0.88 MAPK14 (0.43) TDO2MAPK14CYP1A1CYP1A2CYP1B1
SCHEMBL722329 0.83 SIRT1 (0.33) TDO2SIRT1GRM5NOTUMCYP1A1
SCHEMBL723046 0.81 CSNK2A2 (0.36) TDO2CYP1A1CYP1A2CYP1B1SLC9A1
SCHEMBL722060 0.81 CYP1A1 (0.47) CYP1A1CYP1A2CYP1B1
SCHEMBL721875 0.78 CSNK2A2 (0.40)
SCHEMBL723457 0.77 CYP1A1 (0.36) CYP1A1CYP1A2CYP1B1
SCHEMBL724610 0.76 CYP1A1 (0.41) CYP1A1CYP1A2CYP1B1SLC9A1
SCHEMBL722131 0.76 CYP1A2 (0.44) CYP1A1CYP1A2CYP1B1
SCHEMBL27264184 0.76 S1PR1 (0.32) CYP1A1CYP1A2CYP1B1
SCHEMBL721335 0.76 SYK (0.45) CYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB TDO2 3086/4885SIRT1 945/4885GRM5 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.